{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalCondition"
  ],
  "@id": "health-sciences:medicine:pulmonology:pulm-002",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:51:20.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "pulmonology-knowledge-base"
    ],
    "confidence": 0.96,
    "status": "validated",
    "modified": "2026-01-11T14:42:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/pulmonology",
    "type": "management",
    "difficulty": "intermediate",
    "importance": "critical",
    "aku_id": "002",
    "keywords": [
      "COPD exacerbation",
      "AECOPD",
      "bronchodilators",
      "steroids",
      "antibiotics",
      "respiratory failure"
    ],
    "medical_specialty": "pulmonology",
    "clinical_context": "acute_respiratory"
  },
  "content": {
    "title": "COPD Exacerbation (AECOPD)",
    "summary": "Acute worsening of respiratory symptoms in COPD requiring escalation of therapy",
    "key_points": [
      "Triad: worsened dyspnea, increased sputum volume, sputum purulence",
      "Triggers: viral infection (most common), bacterial infection, environmental",
      "Treatment: bronchodilators, systemic steroids (5 days), \u00b1 antibiotics",
      "Antibiotics if purulent sputum or need for mechanical ventilation",
      "NIV reduces intubation and mortality in hypercapnic respiratory failure",
      "Prevent future exacerbations with optimized COPD therapy"
    ],
    "statement": {
      "text": "COPD exacerbation (AECOPD) is an acute worsening of respiratory symptoms beyond normal day-to-day variation, requiring escalation of treatment. Management includes short-acting bronchodilators, systemic corticosteroids (prednisone 40mg \u00d7 5 days), and antibiotics when indicated by purulent sputum or severe exacerbation.",
      "formal": "AECOPD Treatment = SABA/SAMA + Systemic steroids (5 days) + Antibiotics (if purulent sputum/severe) \u00b1 NIV (if hypercapnic failure)"
    },
    "explanation": {
      "intuition": "An exacerbation is like a sudden storm in already damaged lungs. The already narrowed airways become more inflamed and constricted, mucus production increases, and gas exchange worsens. Quick treatment with bronchodilators and steroids calms the storm.",
      "key_insight": "NIV is the key intervention that reduces intubation and death in AECOPD with hypercapnic respiratory failure. Early application of BiPAP can prevent the need for invasive ventilation."
    },
    "definitions_glossary": {
      "AECOPD": "Acute exacerbation of COPD - worsening symptoms requiring therapy change",
      "Anthonisen_criteria": "Classic triad: increased dyspnea, sputum volume, sputum purulence",
      "purulent_sputum": "Yellow-green sputum suggesting bacterial infection",
      "hypercapnic_respiratory_failure": "Elevated CO2 (PaCO2 >45) with respiratory acidosis",
      "NIV": "Non-invasive ventilation - BiPAP/CPAP without intubation",
      "BiPAP": "Bilevel positive airway pressure - assists ventilation non-invasively",
      "short_course_steroids": "Prednisone 40mg \u00d7 5 days (REDUCE trial)",
      "frequent_exacerbator": "\u22652 moderate or \u22651 severe (hospitalized) exacerbation per year",
      "SABA": "Short-acting beta-agonist (albuterol)",
      "SAMA": "Short-acting muscarinic antagonist (ipratropium)",
      "type_I_exacerbation": "All 3 Anthonisen criteria present (severe)",
      "type_II_exacerbation": "2 of 3 criteria present (moderate)"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "triggers": [
        "Viral infections (rhinovirus, influenza, RSV) - most common",
        "Bacterial infections (H. influenzae, S. pneumoniae, M. catarrhalis, P. aeruginosa)",
        "Environmental pollutants",
        "Cold air exposure",
        "Medication non-adherence"
      ],
      "mechanism": "Trigger \u2192 airway inflammation \u2192 bronchospasm + increased mucus \u2192 worsened obstruction \u2192 V/Q mismatch \u2192 hypoxemia \u00b1 hypercapnia"
    },
    "diagnostic_criteria": {
      "clinical_features": [
        "Worsened dyspnea beyond day-to-day variation",
        "Increased cough frequency/severity",
        "Increased sputum volume and/or purulence",
        "Wheezing, chest tightness"
      ],
      "severity_classification": {
        "mild": "Managed with short-acting bronchodilators alone",
        "moderate": "Requires systemic steroids and/or antibiotics",
        "severe": "Requires hospitalization or emergency visit"
      },
      "workup": [
        "ABG if respiratory distress (assess for hypercapnia)",
        "CXR to exclude pneumonia/pneumothorax",
        "Procalcitonin may guide antibiotic use",
        "ECG if cardiac cause suspected"
      ]
    },
    "treatment_options": {
      "bronchodilators": {
        "SABA": "Albuterol nebulizer 2.5mg or MDI 4-8 puffs q1-4h",
        "SAMA": "Ipratropium nebulizer 0.5mg or MDI 4-8 puffs q4-6h",
        "combination": "Albuterol/ipratropium (DuoNeb) often used together"
      },
      "systemic_steroids": {
        "dose": "Prednisone 40mg PO daily \u00d7 5 days",
        "evidence": "REDUCE trial showed 5-day course as effective as 14-day",
        "IV_steroids": "Methylprednisolone 40-60mg IV if unable to take PO"
      },
      "antibiotics": {
        "indications": [
          "Purulent sputum (yellow/green)",
          "Moderate-severe exacerbation",
          "Mechanical ventilation required"
        ],
        "agents": {
          "outpatient": "Amoxicillin-clavulanate, azithromycin, or doxycycline \u00d7 5-7 days",
          "inpatient_with_Pseudomonas_risk": "Levofloxacin or piperacillin-tazobactam"
        }
      },
      "oxygen_therapy": "Target SpO2 88-92% (avoid over-oxygenation \u2192 suppress hypoxic drive)",
      "NIV": {
        "indication": "Hypercapnic respiratory failure (pH <7.35, PaCO2 >45)",
        "settings": "BiPAP: start IPAP 10-12, EPAP 4-5; titrate to reduce work of breathing",
        "benefit": "Reduces intubation by 65%, mortality by 46%"
      },
      "intubation": "If NIV fails, worsening mental status, or hemodynamic instability"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "COPD Exacerbation"
    },
    "altLabel": [
      {
        "@language": "en",
        "@value": "AECOPD"
      },
      {
        "@language": "en",
        "@value": "Acute Exacerbation of COPD"
      }
    ],
    "definition": {
      "@language": "en",
      "@value": "Acute worsening of respiratory symptoms in COPD beyond normal day-to-day variation requiring escalation of therapy"
    },
    "notation": "pulm-002"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "195951007",
      "uri": "http://snomed.info/id/195951007",
      "description": "Acute exacerbation of COPD",
      "matchType": "exactMatch"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "J44.1",
      "description": "COPD with acute exacerbation",
      "matchType": "exactMatch"
    }
  ],
  "pedagogical": {
    "target_audience": [
      "internal_medicine_residents",
      "pulmonology_fellows",
      "emergency_medicine_physicians",
      "hospitalists"
    ],
    "estimated_time": "35min",
    "difficulty_curve": 0.7,
    "learning_objectives": [
      "Recognize AECOPD using Anthonisen criteria",
      "Determine when antibiotics are indicated",
      "Apply NIV for hypercapnic respiratory failure",
      "Use short-course steroids (5 days)",
      "Identify and address modifiable exacerbation risk factors"
    ],
    "clinical_pearls": [
      "5-day steroid course = 14-day course (REDUCE trial)",
      "Antibiotics only if purulent sputum or severe exacerbation",
      "Target SpO2 88-92% - over-oxygenation can worsen hypercapnia",
      "NIV reduces intubation by 65% - use early in hypercapnic failure",
      "Every hospitalized exacerbation increases future exacerbation risk"
    ],
    "board_yield": {
      "usmle_step2": "Very High",
      "internal_medicine_boards": "Critical"
    }
  },
  "relationships": {
    "prerequisites": [
      {
        "id": "health-sciences:medicine:pulmonology:pulm-001",
        "title": "COPD Definition",
        "strength": 1.0
      }
    ],
    "skos:broader": [
      {
        "@id": "health-sciences:medicine:pulmonology:pulm-001",
        "@type": "skos:Concept",
        "skos:prefLabel": "COPD Definition"
      }
    ],
    "skos:related": [
      {
        "@id": "health-sciences:medicine:pulmonology:pulm-013",
        "@type": "skos:Concept",
        "skos:prefLabel": "Non-invasive Ventilation"
      },
      {
        "@id": "health-sciences:medicine:pulmonology:pulm-029",
        "@type": "skos:Concept",
        "skos:prefLabel": "Respiratory Failure Types"
      }
    ],
    "owl:sameAs": [
      "http://snomed.info/id/195951007",
      "http://www.wikidata.org/entity/Q2538689"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T14:42:00.000Z",
    "sources": [
      {
        "source": "GOLD 2024 Report",
        "type": "clinical_guideline",
        "year": 2024,
        "confidence": 1.0
      },
      {
        "source": "Leuppi JD, et al. Short-term vs conventional glucocorticoid therapy in AECOPD (REDUCE). JAMA 2013",
        "type": "primary_literature",
        "year": 2013
      }
    ]
  },
  "quality_assessment": {
    "CQS": 0.94,
    "completeness": 0.95,
    "accuracy": 0.96,
    "clarity": 0.94,
    "pedagogical_quality": 0.93,
    "ontology_alignment": 0.94,
    "last_assessment": "2026-01-11T14:42:00.000Z",
    "assessor": "quality-enhancement-agent"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Acute_exacerbation_of_COPD",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q2538689"
}